Abstract
Pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD) is associated with an increase in the risk of COPD exacerbation, increased hospitalization, and worse survival in this patient population. No specific treatment is available for PH in COPD. However, reported out-of-proportion PH may benefit from a certain type of treatment. This study shows that the use of selexipag in the treatment of out-of-proportion PH in COPD patients was associated with an improvement in functional status evaluated by a six-minute walk test (6MWT) and a mean pulmonary artery pressure at 6 +/- 2 months of treatment.
Highlights
Pulmonary hypertension (PH) is defined as an increase in the mean pulmonary artery pressure of ⩾ 20 mmHg at rest or >30 mmHg during exercise, which can complicate left heart and pulmonary diseases and result in right heart failure [1,2]
We reviewed the medical records of chronic obstructive pulmonary disease (COPD) patients who were started on selexipag for out-of-proportion pulmonary hypertension
The patient's functional status was assessed by 6MWT which has improved after treatment with selexipag with a total mean change of 97 meters
Summary
Pulmonary hypertension (PH) is defined as an increase in the mean pulmonary artery pressure (mPAP) of ⩾ 20 mmHg at rest or >30 mmHg during exercise, which can complicate left heart and pulmonary diseases and result in right heart failure [1,2]. COPD patients with "out-of-proportion" pulmonary - where resting mPAP was ≥ 35 mmHg in the presence of relatively preserved lung function hypertension - underwent several trials using pulmonary arterial hypertension (PAH)-directed therapy, including prostacyclin agonists, phosphodiesterase type 5 (PDE-5) inhibitors, and nitric oxide-cyclic guanosine monophosphate enhancers. These studies showed mixed effects on resting and exercise-induced pulmonary hemodynamics, six-minute walk test (6MWT), and quality of life [4]. We will evaluate the effect of selexipag on functional capacity in COPD patients with out-ofproportion pulmonary hypertension through the 6MWT and mean pulmonary artery pressure before and after selexipag treatment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
